|
money into original medicine R&D. In these circumstances, if Korean pharmaceuticals companies don’t have any specific strategies to manufacture profitable medicine products compared with decreased price, they will have difficulty in surviving in the positive list system mechanism, and competing for
|
|
메뉴펼치기
